Alasdair is a leader in KPMG’s Precision Medicine practice. He has over 20 years experience in strategy consulting and market research specializing in inorganic growth and commercial strategy and portfolio optimization for biopharmaceutical, genomic, diagnostic and health system clients, as well as private investors. He has also worked with numerous pre-revenue biotechnology companies to help them shape their equity story in preparation for capital raise. As a trained cancer biologist Alasdair helps clients solve complex business problems that require deep scientific and technical knowledge, and he has worked across multiple therapeutic areas, including CNS, hematology, immunology, infectious disease, metabolic diseases, oncology, respiratory, women’s health, as well as rare and ultra-rare diseases. A particular focus is in cell and gene therapies across both in vivo and ex vivo approaches and all modalities and therapy areas. He has led numerous buy-side commercial due diligence projects for strategics and private investors looking to deploy capital in the cell and gene space, and he recently authored a thought leadership piece on the challenges in “one-and-done” gene therapies.